Cite
Polymorphism of formyl peptide receptor 1 (FPR1) reduces the therapeutic efficiency and antitumor immunity after neoadjuvant chemoradiotherapy (CCRT) treatment in locally advanced rectal cancer.
MLA
Chiang, Shu-Fen, et al. “Polymorphism of Formyl Peptide Receptor 1 (FPR1) Reduces the Therapeutic Efficiency and Antitumor Immunity after Neoadjuvant Chemoradiotherapy (CCRT) Treatment in Locally Advanced Rectal Cancer.” Cancer Immunology, Immunotherapy : CII, vol. 70, no. 10, Oct. 2021, pp. 2937–50. EBSCOhost, https://doi.org/10.1007/s00262-021-02894-8.
APA
Chiang, S.-F., Huang, K. C.-Y., Chen, W. T.-L., Chen, T.-W., Ke, T.-W., & Chao, K. S. C. (2021). Polymorphism of formyl peptide receptor 1 (FPR1) reduces the therapeutic efficiency and antitumor immunity after neoadjuvant chemoradiotherapy (CCRT) treatment in locally advanced rectal cancer. Cancer Immunology, Immunotherapy : CII, 70(10), 2937–2950. https://doi.org/10.1007/s00262-021-02894-8
Chicago
Chiang, Shu-Fen, Kevin Chih-Yang Huang, William Tzu-Liang Chen, Tsung-Wei Chen, Tao-Wei Ke, and K S Clifford Chao. 2021. “Polymorphism of Formyl Peptide Receptor 1 (FPR1) Reduces the Therapeutic Efficiency and Antitumor Immunity after Neoadjuvant Chemoradiotherapy (CCRT) Treatment in Locally Advanced Rectal Cancer.” Cancer Immunology, Immunotherapy : CII 70 (10): 2937–50. doi:10.1007/s00262-021-02894-8.